F
ollowing surgery, effective postsurgical pain management is essential because most patients experience pain that often persists for several days or even weeks. For a wide range of surgical procedures, local anesthetics administered via an epidural injection, peripheral nerve blocks, or local infiltrations are commonly used to provide postoperative analgesia. However, the duration of analgesic action of local anaesthetics is typically less than 12 hours. 1 Bupivacaine is among the most widely used long-acting local anesthetics with its moderate onset and long duration of action demonstrated in preclinical and clinical studies. 2, 3 However, longer acting local anesthetics are known to induce systemic toxicity, mostly in relation to the central nervous system (excitation) and cardiovascular system (depression). 2, 3 The cardiotoxicity of bupivacaine and its effects on the QTc interval have been demonstrated in preclinical studies. Besides its known sodium channelblocking properties, it has been shown to block calcium and potassium channels. The effects of bupivacaine on human cloned cardiac delayed rectifier potassium channels have been described by Gristwood. 3 Blocking potassium channels can lengthen cardiac action potential, leading to serious arrhythmias. 3 One study in dogs showed that administration of 4 mg/kg bupivacaine significantly prolonged the QTc interval by more than 25%. 4 Cardiovascular effects of bupivacaine were also demonstrated in clinical studies. In one such study, patients were administered 40 mL of bupivacaine 5 mg/mL for scheduled shoulder arthroscopy. A significant prolongation of the PQ interval was seen 125 minutes postapplication of bupivacaine, which remained significantly prolonged until 6 hours postdose. 5 Double-blind crossover studies in healthy human volunteers have demonstrated that a maximum dose of 48 mg bupivacaine (maximum plasma concentration of 2.25 mg/L) significantly increased the QTc interval by 26.9 ms. 6 Another study showed that in subjects receiving more than 75 mg bupivacaine, the maximum increase in the QTc interval was 24 ms (P = .022).
greatly simplifying postoperative pain management and reducing the need for repeated administration. EXPAREL has recently been submitted and accepted for Food and Drug Administration (FDA) review (December 2010). EXPAREL consists of microscopic, spherical, lipid-based particles (the DepoFoam drug delivery system) composed of a honeycomb of numerous, nonconcentric, internal aqueous chambers containing the encapsulated drug. Each chamber is separated from adjacent chambers by lipid membranes. In vivo, the DepoFoam particles release drug over an extended period of time by erosion and/or reorganization of the particles' lipid membranes. The DepoFoam drug delivery system currently has 2 formulations that have been approved by the US FDA and the European Medicines Agency. 8 QT interval side effects of conventional bupivacaine are known, 6, 9, 10 and therefore, to quantify these effects at relevant dose levels for this formulation (EXPAREL), a formal, thorough QT study was conducted. The purpose of this study was to characterize the effect on QTc of single subcutaneous (SC) administration of EXPAREL (300, 450, 600, and 750 mg) compared with placebo on the largest timematched mean QTc variation, from baseline to under treatment values. This thorough QT/QTc study was conducted in accordance with the International Conference on Harmonisation (ICH) E14 guidelines. The study was performed in 2 parts: part 1 examined the effect of EXPAREL 300 mg and 450 mg SC on the QTc interval in healthy individuals compared to placebo. The maximum dose was set for safety reasons, taking into account the maximum recommended dose of 400 mg over 24 hours. However, an exploratory arm (part 2) was added to investigate higher doses of EXPAREL (600 and 750 mg SC) when plasma levels were found to be lower than anticipated in the lower doses. In part 1 only, 400 mg moxifloxacin was used as a positive control to confirm assay sensitivity.
RESULTS

Participants
The study population for part 1 consisted of 49 healthy, nonsmoking, male and female participants. Participants were excluded if they had a history or presence of clinically significant conditions (including cardiovascular disease, a clinically significant history or family history of congenital long QT syndrome) or had an abnormal electrocardiogram (ECG; PR consistently <120 or >230 ms, QRS consistently >120 ms, QTcB >430 ms for men and >450 ms for women) or were using concomitant medication. For part 2 of the study, 16 of the 49 participants were available. All participants provided written informed consent prior to any study-specific procedures being undertaken.
Participant Demographics and Disposition
A total of 49 participants were included in the first part of the study and randomized to a sequence of 4 treatments. Of the participants, 69.4% were men and 30.6% were women. The mean (SD) age was 26 (5) years with body mass index (BMI) ranging from 19.1 to 29.0 kg/m 2 . With the exception of participants who were on contraception, no concomitant medication was administered during the study. Three participants did not complete the study, 2 withdrew consent for personal reasons, and 1 withdrew because of unforeseen family reasons.
Of the 46 participants completing part 1 of the study, 16 were available for inclusion in part 2; 62.5% were men and 37.5% were women, with a mean (SD) age of 27 (6) . Two participants received concomitant medication during the study: 1 received paracetamol for fever and tonsillitis and the other ibuprofen for thrombophlebitis. There were no withdrawals, and all 16 participants completed the study.
Effects of Moxifloxacin 400 mg on QTcI
Mean QTcI was prolonged in participants receiving moxifloxacin 400 mg compared with placebo ( Figure 1 ). From 0 hour onward, the point estimates of the difference from placebo in QTcI ranged from 0.05 to 11.91 ms. The largest time-matched difference in QTcI for moxifloxacin compared with placebo was observed at 1 hour postdose (mean [2-sided 95% confidence interval (CI)], 11.91 [9.45-14 .38] ms; Table I ). A similar pattern was seen when heart rate was corrected using QTcF with the largest time-matched difference in QTcF occurring at 3 hours postdose (mean [2-sided 95%], 11.27 [8.78-13 .76] ms; data not shown).
Effects of EXPAREL 300 and 450 mg on QTcI
No prolongation of mean QTcI was observed in participants receiving EXPAREL 300 and 450 mg compared to placebo (Figure 1 ). From 0 hour onwards, the point estimate of the difference from placebo in QTcI ranged from -2.24 to 0.81 ms (300-mg dose) and from -2.45 to 0.95 ms (450-mg dose). The largest time-matched difference in QTcI for EXPAREL 300 mg compared with placebo was observed at 8 hours postdose (mean [2- 
Effects of EXPAREL 600 and 750 mg on QTcI
In a similar manner, no prolongation of mean QTcI was observed in the 16 participants receiving EXPAREL 600 and 750 mg compared with placebo ( Figure 1 ). From 0 hour onward, the point estimate of the difference from placebo in QTcI ranged from -3.60 to 2.30 ms (600-mg dose) and from -7.76 to -0.39 ms (750-mg dose). The largest time-matched difference in QTcI for EXPAREL 600 mg compared with placebo was observed at 76 hours postdose (mean [2- 
Categorical Analysis
No participants receiving EXPAREL 300 or 450 mg in part 1 or EXPAREL 600 or 750 mg in part 2 had a maximum QTcI value greater than 500 ms during the study. No participants receiving moxifloxacin 400 mg had maximum QTcI values above 500 ms. No changes from baseline in QTcI were greater than 60 ms at any measurement time point.
Safety and Tolerability
Moxifloxacin and EXPAREL were well tolerated by healthy participants in this study. One serious adverse event (SAE) was observed during the study in 1 participant. Acute hepatitis A with eosinophilia was reported following EXPAREL 450-mg administration. The event was reported after she had completed the study and attended her follow-up visit. This finding was, in the opinion of a consultant toxicologist, unlikely to be related to EXPAREL or DepoFoam. No participant was withdrawn from part 1 because of an adverse event (AE). Overall, 60 AEs were reported by 25 part 1 participants, of whom 17 had AEs considered to be treatment related. This included nausea following moxifloxacin treatment and abdominal pain, injection site irritation, and headache following EXPAREL treatment. Twenty-four participants (49%) did not report any AEs, 25 (51%) reported mild AEs, and 1 (2%) reported a moderate event. The most frequently reported AEs included nervous system, gastrointestinal, and respiratory/thoracic disorders. With the exception of clinical chemistry findings associated with the SAE, there were no clinically significant changes in laboratory parameters, vital signs, or individual ECG parameters. 
DISCUSSION
Thorough QT/QTc studies are performed to determine whether a drug has an effect on cardiac repolarization as detected by QT/QTc prolongation. These studies are usually carried out during early stages of clinical development as delayed repolarization can lead to the development of critical cardiac arrhythmias such as torsades de pointes. The measured QT interval is normally transformed by various heart rate correction formulas into a value termed the corrected QT interval (QTc), which is independent of heart rate.
Thorough QT/QTc studies require the use of a positive comparator that can confirm the validity of the methodology used and provide a background for the effects of the investigational drug. Currently, as defined by the ICH E14 guidelines, the threshold level for regulatory concern is a QT/QTc prolongation of around 5 ms, as evidenced by an upper bound of the 95% CI of the mean effect around 10 ms.
11
In part 1 of this study, moxifloxacin was used as a positive comparator, and the observed QTc prolongation of 11.91 ms, with an upper limit of the 2-sided 95% CI interval greater than 10 ms, confirmed the validity of this assay and its ability to detect clinically significant changes in QTc.
The ICH E14 guidelines state that a negative "thorough QT/QTc study" is one where the largest time-matched mean difference between the drug and placebo for QTc is not greater than 5 ms, with a CI that excludes an effect of 10 ms or greater. In part 1, 300 and 450 mg EXPAREL produced mean QTcI shortening of -2.24 ms and -2.45 ms, respectively, with an upper limit of the 2-sided 95% CI less than 10 ms. A similar pattern was observed in part 2 with a mean QTcI prolongation of -3.6 ms (600 mg) and -7.67 ms (750 mg), with an upper limit of the 2-sided 95% CI less than 10 ms. The findings of this study suggest that all tested doses of EXPAREL do not have any clinically significant effect on QTc. In fact, all 4 doses of EXPAREL produced a slight shortening of the QTc interval, but only in the 600-mg dose did this not reach significance with the 2-sided 95% CI, including zero.
The assay in this study has been previously used and validated at the study site in 3 previous thorough QT/QTc studies. In each study, moxifloxacin was shown to produce QTc prolongation of 14.81 (13.50-16.11) ms, 10.59 (7.95-13.23) ms, and 13.19 (11.21-15.17) ms. These values are in agreement with previously published values of QTc prolongation with moxifloxacin, further confirming the validity of the assay used in this QT/QTc study. [12] [13] [14] Both moxifloxacin and EXPAREL were generally well tolerated in healthy participants. The most commonly reported AEs as defined by MedDRA included nervous system disorders (26.5%), gastrointestinal disorders (22.4%), respiratory/thoracic disorders (14.3%), and injury, poisoning, and procedural disorders (25.0%). Overall, treatment-related AEs were reported by 17 (34.7%) participants during part 1 and 8 (50.0%) participants during part 2 of the study.
In conclusion, all 4 doses of EXPAREL did not show any clinically significant effect on QTc; a slight shortening of the QTc interval was observed (more than placebo), which appeared to be dose dependent. The clinical significance of shortening the QTc interval in the region of 5 ms is not known but currently considered of no clinical concern.
11 QTc shortening has also been described in published data for other medicines. 15 This study shows that bupivacaine given subcutaneously as a new extendedrelease formulation (EXPAREL) in doses of up to 750 mg does not prolong the QT interval and raises no cardiac concerns.
METHODS
Study Design
Part 1 was a single-center, randomized, doubleblind, placebo-and positive-controlled, double-dummy (placebo and moxifloxacin randomized), crossover study (300 and 450 mg). Participants attended for screening, run-in assessment, 5 treatment periods, and a follow-up visit. Part 2 was a single-center, sequential-dose, exploratory extension, open-label study (600 and 750 mg). Participants attended for screening, 2 treatment periods, a total of 8 outpatient visits, and a follow-up visit. Higher doses were used as plasma concentrations from 300 and 450 mg were lower than expected. As part 2 was to be completed by the same participants who participated in part 1, a positive comparator was not used in this study period.
For both parts of the study, the lack of a carryover effect was confirmed by comparing raw pharmacokinetic (PK) data at the zero hour time point and baseline QTc values for all periods (data not shown).
The 
Electrocardiogram Assessments and QTc Evaluation
Twelve-lead ECGs were recorded using a MAC1200 recorder (GE Healthcare, Bucks, UK), and all ECGs were stored electronically on the MUSE CV information system (GE Healthcare). For part 1 of the study, the recordings were made for 24 hours after dosing with placebo/moxifloxacin (periods 1 and 2) and for 96 hours after dosing with placebo/EXPAREL (periods 3, 4, and 5). During part 2, ECG recordings were made for 96 hours after dosing on day 1 (periods 1 and 2).
At each time point, ECGs were recorded in triplicate (for 10 seconds at 1-minute intervals during 3 minutes) to reduce the variance and improve the precision of measurement. ECGs were recorded after each study drug administration and at baseline (day -1). Baseline constituted the time-matched reference period used for the calculation of the baseline composite. The participants maintained an undisturbed supine resting position for at least 10 minutes prior to ECG recording and avoided postural changes during the ECG recordings.
Data Analysis and Statistical Methods
Effect on QT/QTc interval was analyzed using the largest time-matched mean difference between moxifloxacin/EXPAREL and placebo (baseline adjusted). ECGs were taken in triplicate at each time point, and the QTc interval was expressed as the mean of these 3 values. Each treatment period had a baseline day and treatment day. For each treatment, the QT/QTc interval value change at each time point was expressed as the difference between baseline and treatment day from baseline (∆QTc). The effect size was determined as the time-matched, baseline-adjusted QT/QTc interval value for EXPAREL/ moxifloxacin versus placebo (∆∆QTc). 16 Measurement of the QT interval was performed automatically with subsequent manual on-screen over-reading using electronic calipers (MUSE CV Interval Editor; GE Healthcare) by cardiologists with extensive experience with manual QT measurement (including on-screen measurement with electronic calipers) from the Department of Cardiological Sciences, St George's University of London.
All ECGs were included in the QT correction analysis except for those ECGs that were excluded by the cardiologists as nonevaluable. Among the 4 correction formulas (individual, population, Fridericia, and Bazett), the best correction was determined by the statistician under blinded conditions based on the mean squared error approach. 17 Having considered the number of available ECGs per participant and the heart rate range, the primary criterion was determined to be QTcI as the most accurate heart rate correction. 7 All statistical analyses were performed using SAS 9.1 software (SAS Institute, Cary, North Carolina).
Sample size was chosen and determined empirically for part 1, which was considered adequate to meet the study objectives. For part 2 (explorative study), sample size was not based on statistical considerations.
Safety Assessments
Safety analysis included all treatment-emergent AEs, laboratory tests (hematology, biochemistry, and urinalysis) and physical examinations (vital signs assessment).
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